Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...
Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making. An analysis of 10 years of decision-making by health ...
Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback